Use of sirolimus in the treatment of refractory autoimmune hepatitis

Hemant Chatrath, Larissa Allen, Thomas D. Boyer

Research output: Contribution to journalArticlepeer-review

42 Scopus citations


BACKGROUND: Corticosteroids and azathioprine are widely accepted as the initial therapy for autoimmune hepatitis. However, the disease is refractory to steroids in about 10%-20% of patients, for whom currently there is no standardized treatment. Here we describe our experience with sirolimus in treatment of steroid refractory autoimmune hepatitis. METHODS: This is a longitudinal follow-up study. Between November 2007 and January 2014, 5 subjects with steroid refractory autoimmune hepatitis were treated with sirolimus at our institution. RESULTS: A response, defined as a sustained >50% fall in alanine aminotransferase (ALT) levels, was achieved in 4/5 patients. A complete response, sustained normalization of ALT levels, was achieved in 2/5 patients. The need for steroids was significantly reduced in all patients (P < .05). CONCLUSIONS: In this small series, sirolimus appears to be useful in the treatment of patients with steroid refractory autoimmune hepatitis.

Original languageEnglish (US)
Pages (from-to)1128-1131
Number of pages4
JournalAmerican Journal of Medicine
Issue number11
StatePublished - Nov 1 2014


  • Autoimmune hepatitis
  • Sirolimus
  • Steroid-refractory

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Use of sirolimus in the treatment of refractory autoimmune hepatitis'. Together they form a unique fingerprint.

Cite this